Kyowa Kirin (4151) Investor presentation summary

Vision and strategic focus

• Aims to deliver life-changing value by addressing unmet medical needs through innovative pharmaceuticals, focusing on patient-centric healthcare and operational excellence.

• Emphasizes developing therapies for diseases lacking effective treatments, leveraging biotechnology and advanced drug delivery.

• Seeks to build long-term trust with stakeholders through quality and innovation.

KHK4951 program overview

• KHK4951 is being developed as an eye drop for maintenance therapy in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

• Targets a significant market with millions of global patients and a market size estimated at up to 1 trillion yen.

• Aims to reduce the burden of frequent intravitreal injections by offering a non-invasive alternative.

• Utilizes nanocrystallized tivozanib for efficient posterior eye delivery.

Clinical need and treatment concept

• nAMD requires ongoing anti-VEGF intravitreal injections, which are burdensome for patients and healthcare providers.

• KHK4951 proposes a maintenance strategy centered on daily eye drops, potentially reducing injection frequency and clinic visits.

• Envisions self-managed daily therapy with professional intervention only as needed.